REGENXBIO Inc. (RGNX)

REGENXBIO Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-263.49	-280.32	127.84	-111.25	-94.73
Depreciation & Amortization	17.32	12.91	9.56	8.41	7.15
Share-Based Compensation	40.27	40.79	38.81	31.95	26.85
Other Operating Activities	-12.5	19.14	42.66	16.83	-46.98
Operating Cash Flow	-218.41	-207.49	218.88	-54.06	-107.71
Capital Expenditures	-9.96	-30.72	-84.18	-26.87	-11.72
Change in Investments	200.9	18.8	-322.47	149.63	105.28
Investing Cash Flow	190.94	-11.93	-406.64	122.76	93.56
Share Issuance / Repurchase	8.22	4.55	222.49	7.42	8.38
Other Financing Activities	-43.19	-33.39	-27.24	192.79	-
Financing Cash Flow	-34.97	-28.84	195.25	200.21	8.38
Net Cash Flow	-62.43	-248.26	7.48	268.91	-5.77
Free Cash Flow	-228.37	-238.21	134.7	-80.93	-119.43
Free Cash Flow Margin	-253.06%	-211.32%	28.64%	-52.36%	-338.96%
Free Cash Flow Per Share	-5.22	-5.52	3.17	-2.17	-3.25

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).